These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38048511)

  • 21. Rapid Rollout and Initial Uptake of a Booster COVID-19 Vaccine Among Israel Defense Forces Soldiers.
    Talmy T; Nitzan I
    J Prev (2022); 2023 Feb; 44(1):1-14. PubMed ID: 35972594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is stronger religious faith associated with a greater willingness to take the COVID-19 vaccine? Evidence from Israel and Japan.
    Lahav E; Shahrabani S; Rosenboim M; Tsutsui Y
    Eur J Health Econ; 2022 Jun; 23(4):687-703. PubMed ID: 34677722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021-January 8, 2022.
    Danza P; Koo TH; Haddix M; Fisher R; Traub E; OYong K; Balter S
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(5):177-181. PubMed ID: 35113851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of the Covid-19 pandemic on patient visits to the emergency department and hospitalizations in medical wards in an Israeli medical center.
    Frenkel Nir Y; Levy Y; Gutkind A; Grossman E
    Isr J Health Policy Res; 2021 Nov; 10(1):62. PubMed ID: 34724976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021-July 2022.
    Petrie JG; King JP; McClure DL; Rolfes MA; Meece JK; Pattinson D; Neumann G; Kawaoka Y; Belongia EA; McLean HQ
    Influenza Other Respir Viruses; 2023 Mar; 17(3):e13104. PubMed ID: 36875208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022.
    Johnson AG; Linde L; Ali AR; DeSantis A; Shi M; Adam C; Armstrong B; Armstrong B; Asbell M; Auche S; Bayoumi NS; Bingay B; Chasse M; Christofferson S; Cima M; Cueto K; Cunningham S; Delgadillo J; Dorabawila V; Drenzek C; Dupervil B; Durant T; Fleischauer A; Hamilton R; Harrington P; Hicks L; Hodis JD; Hoefer D; Horrocks S; Hoskins M; Husain S; Ingram LA; Jara A; Jones A; Kanishka FNU; Kaur R; Khan SI; Kirkendall S; Lauro P; Lyons S; Mansfield J; Markelz A; Masarik J; McCormick D; Mendoza E; Morris KJ; Omoike E; Patel K; Pike MA; Pilishvili T; Praetorius K; Reed IG; Severson RL; Sigalo N; Stanislawski E; Stich S; Tilakaratne BP; Turner KA; Wiedeman C; Zaldivar A; Silk BJ; Scobie HM
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(6):145-152. PubMed ID: 36757865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Delta and Omicron Variant Predominance, by Race/Ethnicity and Vaccination Status - COVID-NET, 14 States, July 2021-January 2022.
    Taylor CA; Whitaker M; Anglin O; Milucky J; Patel K; Pham H; Chai SJ; Alden NB; Yousey-Hindes K; Anderson EJ; Teno K; Reeg L; Como-Sabetti K; Bleecker M; Barney G; Bennett NM; Billing LM; Sutton M; Talbot HK; McCaffrey K; Havers FP;
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(12):466-473. PubMed ID: 35324880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccinations versus Lockdowns to Prevent COVID-19 Mortality.
    Arbel R; Pliskin J
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study.
    Mateo-Urdiales A; Sacco C; Fotakis EA; Del Manso M; Bella A; Riccardo F; Bressi M; Rota MC; Petrone D; Siddu A; Fedele G; Stefanelli P; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M
    Lancet Infect Dis; 2023 Dec; 23(12):1349-1359. PubMed ID: 37478877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study.
    Yamin D; Yechezkel M; Arbel R; Beckenstein T; Sergienko R; Duskin-Bitan H; Yaron S; Peretz A; Netzer D; Shmueli E
    Lancet Infect Dis; 2023 Oct; 23(10):1130-1142. PubMed ID: 37352878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How severe would prioritization-induced bottlenecks need to be offset the benefits from prioritizing COVID-19 vaccination to those most at risk in New York City?
    Kim HY; Bershteyn A; McGillen JB; Braithwaite RS
    BMC Public Health; 2023 Jan; 23(1):174. PubMed ID: 36698103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a nationwide booster vaccine rollout in Israel on SARS-CoV-2 infection and severe illness in young adults.
    Bomze D; Sprecher E; Gamzu R
    Travel Med Infect Dis; 2021; 44():102195. PubMed ID: 34737149
    [No Abstract]   [Full Text] [Related]  

  • 36. Timing, extent and outcomes of public health measures in the first wave of the COVID-19 pandemic in Israel and a comparative analysis by socioeconomic indices.
    Ginzburg A; Barasche-Berdah D; Manor O; Levine-Schnur R; Paltiel O; Levine H
    Isr J Health Policy Res; 2023 Jan; 12(1):5. PubMed ID: 36717901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022.
    McConeghy KW; White EM; Blackman C; Santostefano CM; Lee Y; Rudolph JL; Canaday D; Zullo AR; Jernigan JA; Pilishvili T; Mor V; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(39):1235-1238. PubMed ID: 36173757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addressing vaccine hesitancy and access barriers to achieve persistent progress in Israel's COVID-19 vaccination program.
    Rosen B; Waitzberg R; Israeli A; Hartal M; Davidovitch N
    Isr J Health Policy Res; 2021 Aug; 10(1):43. PubMed ID: 34340714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drawing on Israel's Experience Organizing Volunteers to Operationalize Drive-Through Coronavirus Testing Centers.
    Kim E
    Disaster Med Public Health Prep; 2020 Dec; 14(6):812-814. PubMed ID: 32295659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study.
    Adams K; Rhoads JP; Surie D; Gaglani M; Ginde AA; McNeal T; Talbot HK; Casey JD; Zepeski A; Shapiro NI; Gibbs KW; Files DC; Hager DN; Frosch AE; Exline MC; Mohamed A; Johnson NJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Lauring AS; Khan A; Busse LW; Duggal A; Wilson JG; Chang SY; Mallow C; Kwon JH; Chappell JD; Halasa N; Grijalva CG; Lindsell CJ; Lester SN; Thornburg NJ; Park S; McMorrow ML; Patel MM; Tenforde MW; Self WH;
    BMJ; 2022 Oct; 379():e072065. PubMed ID: 36220174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.